Brought to you by 
Merck gets exclusive rights to probiodrug's inhibitors
09 Jan 2001
Executive Summary
Merck has licensed exclusive worldwide rights to probiodrug's (metabolic diseases and immune and CNS disorders) dipeptidyl peptidase (DP IV) inhibitors to develop orally administered pharmaceuticals for diabetes.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com